Pertuzumab
Clinical Trials Overview
11 trials found
About Pertuzumab
Pertuzumab is a humanized monoclonal antibody that targets HER2-positive colorectal cancers, used in combination with trastuzumab for patients whose tumors overexpress or amplify the HER2 protein. In colorectal cancer, pertuzumab is primarily utilized for HER2-positive metastatic disease, which occurs in approximately 2-3% of colorectal cancer patients. This targeted therapy represents a precision medicine approach for a specific molecular subset of colorectal cancer patients who have limited treatment options.
Category
Immunotherapy
Brand Name
Perjeta
Mechanism
Pertuzumab binds to the extracellular dimerization domain of the HER2 receptor, preventing heterodimerization with other HER family receptors including HER1, HER3, and HER4. By blocking HER2 receptor dimerization, pertuzumab inhibits downstream signaling pathways that promote tumor cell proliferation and survival. When combined with trastuzumab, pertuzumab provides complementary HER2 blockade, as trastuzumab binds to a different epitope on the HER2 receptor.
Efficacy Data by Mutation
Response rates and survival outcomes by patient molecular profile
HER2 GCN ≥20
2A
57.1%
ORR
9.9m
PFS
HER2 ?20
2A
57.1%
ORR
9.9m
PFS
KRAS Wild-Type
2A
34.6%
ORR
4.7m
PFS
n=26
Sample
HER2 3+ or 2+/ISH amplified
2A
34.6%
ORR
4.7m
PFS
n=26
Sample
BRAF Wild-Type
2A
34.6%
ORR
4.7m
PFS
n=26
Sample
HER2 IHC 2+/3+
2A
32%
ORR
4m
PFS
11.5m
OS
n=57
Sample
11
Total Trials
5
Recruiting
2
Active
4
Completed
10,714
Total Enrollment
19
Countries
Research trend for Pertuzumab
Number of trials started per year
Research has declined since peaking at 2 trials in 2015.
Active sites for Pertuzumab
Recruiting sites
19 countries
Phase:
NCT06490536
Phase 3
Recruiting
700 patients
Medications:
5-Fluorouracil
Capecitabine
Ipilimumab
Irinotecan
Leucovorin
Nivolumab
Oxaliplatin
Panitumumab
Pertuzumab
Temozolomide
Trastuzumab
Background \& Rationale:
Colon cancer is a leading cause of cancer deaths, with a high recurrence rate in stage II high-risk and stage III patients due to undetectable micro-metastases. Liquid biopsy (LB) detects residual cancer DNA post-surgery and...
Germany, Italy, Spain
NCT05786716
Phase 2
Recruiting
30 patients
Medications:
Pertuzumab
Trastuzumab
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This ...
United Kingdom
NCT05525858
Not Applicable
Recruiting
1,000 patients
Medications:
Alectinib
Atezolizumab
Bevacizumab
Entrectinib
Erlotinib
Pertuzumab
Pralsetinib
Trastuzumab
Vemurafenib
A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using target...
South Korea
NCT05150691
Phase 1
Recruiting
796 patients
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
United States, Australia, China, Puerto Rico, South Korea, Taiwan
NCT03803553
Phase 3
Recruiting
400 patients
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer.
The names of the potential treatments involved in this study are:
* Active surveillance
* FOLFIRI...
United States
NCT06136897
Phase 2
Active
35 patients
Medications:
Pertuzumab
Trastuzumab
This phase II MATCH treatment trial tests how well trastuzumab and pertuzumab work in treating patients with HER2-amplified non-breast, non-gastric/gastroesophageal junction, and non-colorectal cancers. Pertuzumab and trastuzumab are monoclonal antib...
United States
NCT02465060
Phase 2
Active
6,452 patients
Medications:
Adavosertib
Afatinib
Binimetinib
Capivasertib
Copanlisib
Crizotinib
Dabrafenib
Dasatinib
Defactinib
Erdafitinib
Fexagratinib
Ipatasertib
Larotrectinib
Nivolumab
Osimertinib
Palbociclib
Pertuzumab
Relatlimab
Sapanisertib
Taselisib
Trametinib
Trastuzumab
Ulixertinib
Vismodegib
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, l...
United States, Guam, Puerto Rico
NCT03365882
Phase 2
Completed
240 patients
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in...
United States, Puerto Rico
NCT02291289
Phase 2
Completed
1,044 patients
Medications:
5-Fluorouracil
Atezolizumab
Bevacizumab
Capecitabine
Cetuximab
Cobimetinib
Leucovorin
Oxaliplatin
Pertuzumab
Trastuzumab
Vemurafenib
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have r...
Argentina, Belgium, Bosnia and Herzegovina, Brazil, Denmark, Egypt, France, Germany, Greece, Italy,
NCT03225937
Phase 2
Completed
This is a Phase II multi-center 2-sequential cohorts trial, designed to assess the objective response rate of two anti HER2 combination in advanced disease CRC patients harbouring an amplified HER2 tumor assessed according to HERACLES Diagnostic Crit...
Italy
NCT00551421
Phase 1
Completed
17 patients
Medications:
Cetuximab
Pertuzumab
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving ...
United States